185 related articles for article (PubMed ID: 19915358)
21. Optimizing second-line therapy for chronic myeloid leukemia.
Raja T
Indian J Cancer; 2012; 49(1):46-56. PubMed ID: 22842168
[TBL] [Abstract][Full Text] [Related]
22. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.
Gallipoli P; Stobo J; Heaney N; Nicolini FE; Clark R; Wilson G; Tighe J; McLintock L; Hughes T; Michor F; Paul J; Drummond M; Holyoake TL
Br J Haematol; 2013 Dec; 163(5):674-6. PubMed ID: 24032404
[No Abstract] [Full Text] [Related]
24. [Chronic myeloid leukemia. Diagnostics, therapy and future strategy].
Burchert A; Neubauer A
Internist (Berl); 2011 Mar; 52(3):283-93; quiz 294-5. PubMed ID: 21253680
[TBL] [Abstract][Full Text] [Related]
25. Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy.
Abe A; Minami Y; Hayakawa F; Kitamura K; Nomura Y; Murata M; Katsumi A; Kiyoi H; Jamieson CHM; Wang JYJ; Naoe T
Int J Hematol; 2008 Dec; 88(5):471-475. PubMed ID: 19039626
[TBL] [Abstract][Full Text] [Related]
26. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
27. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
Shah NP; Kim DW; Kantarjian H; Rousselot P; Llacer PE; Enrico A; Vela-Ojeda J; Silver RT; Khoury HJ; Müller MC; Lambert A; Matloub Y; Hochhaus A
Haematologica; 2010 Feb; 95(2):232-40. PubMed ID: 20139391
[TBL] [Abstract][Full Text] [Related]
28. The toxicities of modern targeted therapies: learning from the price of progress.
Giles FJ
Target Oncol; 2009 Apr; 4(2):65-6. PubMed ID: 19357815
[No Abstract] [Full Text] [Related]
29. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Jabbour E; Cortes J; Kantarjian H
Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
[TBL] [Abstract][Full Text] [Related]
30. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Hochhaus A
Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
[TBL] [Abstract][Full Text] [Related]
31. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Defuentes G; Bladé JS; Berets O
N Engl J Med; 2007 Oct; 357(15):1556-7; author reply 1557-8. PubMed ID: 17928609
[No Abstract] [Full Text] [Related]
32. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Cortes J; Kim DW; Raffoux E; Martinelli G; Ritchie E; Roy L; Coutre S; Corm S; Hamerschlak N; Tang JL; Hochhaus A; Khoury HJ; Brümmendorf TH; Michallet M; Rege-Cambrin G; Gambacorti-Passerini C; Radich JP; Ernst T; Zhu C; Van Tornout JM; Talpaz M
Leukemia; 2008 Dec; 22(12):2176-83. PubMed ID: 18754032
[TBL] [Abstract][Full Text] [Related]
33. Leukemia. Q&A highlights.
Frame D; Sessions J; Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S22. PubMed ID: 18056929
[No Abstract] [Full Text] [Related]
34. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Quintás-Cardama A; Cortés JE; Kantarjian H
Clin Lymphoma Myeloma; 2008 Mar; 8 Suppl 3():S82-8. PubMed ID: 19254885
[TBL] [Abstract][Full Text] [Related]
35. [Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group].
Hochhaus A; Berger U; Reiter A; Engelich G; Lahaye T; Kreil S; Merx K; Müller MC; Hehlmann R
Internist (Berl); 2002 Oct; 43(10):1228, 1231-8, 1241-4. PubMed ID: 12524904
[No Abstract] [Full Text] [Related]
36. Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.
Bose P; Perkins EB; Honeycut C; Wellons MD; Stefan T; Jacobberger JW; Kontopodis E; Beumer JH; Egorin MJ; Imamura CK; Douglas Figg W; Karp JE; Koc ON; Cooper BW; Luger SM; Colevas AD; Roberts JD; Grant S
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1657-67. PubMed ID: 22349810
[TBL] [Abstract][Full Text] [Related]
37. Loss of response to imatinib: mechanisms and management.
Shah NP
Hematology Am Soc Hematol Educ Program; 2005; ():183-7. PubMed ID: 16304378
[TBL] [Abstract][Full Text] [Related]
38. Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML.
McCann SR; Gately K; Conneally E; Lawler M
Blood; 2003 Feb; 101(3):1200-1. PubMed ID: 12529295
[No Abstract] [Full Text] [Related]
39. Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.
Breccia M; Alimena G
Curr Drug Targets; 2009 Jun; 10(6):530-6. PubMed ID: 19519355
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT).
Fischer T; Reifenrath C; Hess GR; Corsetti MT; Kreil S; Beck J; Meinhardt P; Beltrami G; Schuch B; Gschaidmeier H; Hehlmann R; Hochhaus A; Carella A; Huber C
Leukemia; 2002 Jul; 16(7):1220-8. PubMed ID: 12094246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
